Turna Ray

The law requires state employee, Medicaid, public school, and small employer plans to cover evidence-based biomarker testing, a change that will readily impact cancer patients.

Researchers used real-world data to identify low NGS testing rates, particularly among Black patients, suggesting many aren't getting precision medical treatment.

At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.

The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.

During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.

WIN Consortium researchers have shown that a prototype "digital display precision predictor" may identify patents who will live longer on treatments without progression.

At the AACR Annual Meeting, Sharpless said NCI should focus on improving early screening, access to trials, and development of advanced drugs to realize President Biden's goal of eradicating cancer.

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

The college wants genetic counselors to work with doctors when ordering genetic tests, but not all medical geneticists agree the stance is good for patients.

The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.